Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder

Journal of Clinical Psychiatry

Volumn 71, Issue 7, 2010, Pages 821-822

  Stahl, Stephen M ^a,b,c  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANDROGEN; BREMELANOTIDE; BUSPIRONE; CYPROHEPTADINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOCANNABINOID; ESTRADIOL; ESTROGEN; LEVODOPA; MELANOCORTIN; MELANOCORTIN RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; OXYTOCIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TIBOLONE;

BRAIN; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG TARGETING; EROTISM; HORMONAL THERAPY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOTHALAMUS; LIBIDO; LIBIDO DISORDER; LIMBIC SYSTEM; MENOPAUSE; NEUROIMAGING; NEUROTRANSMISSION; OFF LABEL DRUG USE; PARKINSON DISEASE; PRIORITY JOURNAL; REWARD; SEROTONINERGIC SYSTEM; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SHORT SURVEY; VIDEORECORDING;

BRAIN; BRAIN MAPPING; DOPAMINE; DOPAMINE AGENTS; EMOTIONS; HORMONE REPLACEMENT THERAPY; HUMANS; LIBIDO; MELANOCORTINS; NERVE NET; OXYTOCIN; PSYCHOTROPIC DRUGS; SEROTONIN; SEROTONIN ANTAGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 77955285504     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10bs06117blu     Document Type: Short Survey

References (12)

1. Stahl SM. Circuits of sexual desire in HSDD (hypoactive sexual desire disorder). J Clin Psychiatry. 2010;71(5):518-519.
2. Stahl SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.
3. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506-1533.
4. Arnow BA, Millheiser L, Garrett A, et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience. 2009;158(2):484-502.
5. Holstege G, Willemsen A, Beers C, et al. 2009. Differences in brain activity in premenopausal women with hypoactive sexual desire disorder (HSDD) compared to women without sexual dysfunction. Presented at the 12th Congress of the European Society for Sexual Medicine. November 16, 2009; Lyon, France.
6. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689.
7. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59.
8. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142.
9. Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. (Pubitemid 43919016)
10. Bortolozzi A, Díaz-Mataix L, Scorza MC, et al. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem. 2005;95(6):1597-1607. (Pubitemid 41804057)
11. Invernizzi RW, Sacchetti G, Parini S, et al. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003;139(7):1281-1288. (Pubitemid 37026411)
12. Jolly E, Clayton A, Thorp J, et al. 2009, Efficacy of flibanserin 100 mg qhs as a potential treatment for hypoactive sexual desire disorder in premenopausal women. Presented at the 12th Congress of the European Society for Sexual Medicine (ESSM). November 16, 2009; Lyon, France.